Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase II atezolizumab in advanced solid tumors
NL-OMON47718Phase 2Active, not recruiting
- Sponsor
- Roche
- Start
- Jul 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab in Nonhematologic neoplasms, sponsored by Roche. Primary endpoint: Non-progression rate at 18 weeks. Started Jul 2015; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON47718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47718.